More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...

In an era of open data, genome-wide association studies have become entangled with efforts to prove Black inferiority.

today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q ...

Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...

Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861 (YUTREPIA) in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

Session Date and Time: April 30, 2025 - 9:00 AM - 12:00 PM CT (10:00 AM - 1:00 PM ET) Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that the Compensation Committee ...